Celgene Corporation company logo

# 1st Gen Model Celgene Corporation Pharmaceutical preparations

  • $133.85Last close price
    at 26-jun-2017
  • Subscribe >> Deal exit on
    June 27, 2017
    Deal entry on
    June 27, 2017
  • 3.48%Expected margin
  • 70.77% successful of 65 deals

CELG

Model's trade recommendations -11.16% Return for period

9.86% Annual return

$104.87B Market Cap

β 1.82  

CELG

Model (following trade recommendations)

CELG

Underlying stock

S&P 500

Index
Return for period -11.16%
15.01%
1.78%
52wk return 6.75%
39.48%
16.82%
52wk Range
94.85—134.31
2000.54—2399.63
Sortino ratio 0.97
Sharpe ratio 0.72
Norm. RMSE 0.67%
Downside risk 10.34%
Volatility 13.88%
  • STRONG BUY Analysts consensus recommendation

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 773M
P/E 23.94
Shares Outstanding 781M
% Held by Insiders 0.95%
% Held by Institutions 78.26%
EPS (last reported FY) $5.18
EPS (last reported Q) $1.53
EPS, estimated (last reported Q) $1.47
Total revenues $11 B
Net income $2 B